Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: Implications for DC vaccination

Critical Reviews in Immunology

Volumn 34, Issue 6, 2014, Pages 517-536

  van Beek, Jasper J P ^a   Wimmers, Florian ^a   Hato, Stanleyson V ^a   de Vries, I Jolanda M ^a,b   Sköld, Annette E ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dendritic cell based cancer vaccines; Dendritic cells; Natural killer cells; Natural killer T cells; T cells

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DENDRITIC CELL VACCINE; ZOLEDRONIC ACID; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CD4+ T LYMPHOCYTE; CELL COMMUNICATION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MOUSE; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSPLANTATION; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84918774816     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.2014012204     Document Type: Article

References (158)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991 Jan;9:271–96.
2. Wimmers F, Schreibelt G, Sköld AE, Figdor CG, De Vries IJM. Paradigm shift in dendritic cellbased immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol. 2014 Jan;5:165.
3. Couzin-Frankel J. Breakthrough of the year 20Cancer immunotherapy. Science. 2013 Dec 20;342(6165):1432–3.
4. De Vries IJM, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen M-JP, Ruiter DJ, Figdor CG, Punt CJA, Adema GJ. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005 Aug 20;23(24): 5779–87.
5. Aarntzen EHJG, De Vries IJM, Lesterhuis WJ, Schuurhuis D, Jacobs JFM, Bol K, Schreibelt G, Mus R, De Wilt JHW, Haanen JBAG, Schadendorf D, Croockewit A, Blokx WAM, Van Rossum MM, Kwok WW, Adema GJ, Punt CJA, Figdor CG. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013 Jan 1;73(1):19–29.
6. Vasaturo A, Di Blasio S, Peeters DGA, de Koning CCH, de Vries JM, Figdor CG, Hato S V. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol. 2013 Jan;4:417.
7. Bubeník J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol. 2004 Aug;25(2):487–91.
8. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D’Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010 Aug;161(2):290–7.
9. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol. 2011 Mar;138(3):255–65.
10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008 May;9(5):503–10.
11. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010 Sep 17;142(6): 847–56.
12. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei X, Liew FY, Caligiuri MA, Durbin JE, Biron CA. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol. 2002 Oct 15;169(8):4279–87.
13. Agaugué S, Marcenaro E, Ferranti B, Moretta L, Moretta A. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood. 2008 Sep 1;112(5):1776–83.
14. Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmüller G, Koszinowski U, Röcken M. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003 Oct;19(4):561–9.
15. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11521–6.
16. Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, Arnon TI, Gazit R, Joseph A, Schjetne KW, Steinle A, Porgador A, Mevorach D, Goldman-Wohl D, Yagel S, LaBarre MJ, Buckner JH, Mandelboim O. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest. 2004 Dec;114(11):1612–23.
17. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004 Sep 15;173(6):3716–24.
18. GeurtsvanKessel CH, Bergen IM, Muskens F, Boon L, Hoogsteden HC, Osterhaus ADME, Rimmelzwaan GF, Lambrecht BN. Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection. PLoS One. 2009 Jan;4(9):e7187.
19. Bouwer AL, Saunderson SC, Caldwell FJ, Damani TT, Pelham SJ, Dunn AC, Jack RW, Stoitzner P, McLellan AD. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol. 2014 Jan 29;192(5):2514–21.
20. Kim A, Noh Y-W, Kim KD, Jang Y-S, Choe Y-K, Lim J-S. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med. 2004 Oct 31;36(5):428–43.
21. Brilot F, Strowig T, Roberts SM, Arrey F, Münz C. NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha. J Clin Invest. 2007 Nov;117(11):3316–29.
22. Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T, Bougras G, Muller WA, Moretta L, Münz C. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606–11.
23. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin Immunity. 2007 Apr;26(4):503–17.
24. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang Y-H, Ye Y, Sikora AG, Overwijk WW, Liu Y-J, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar;118(3):1165–75.
25. Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, Moretta A, Valiante NM, Parham P. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol. 2007 Mar 1;178(5):2688–98.
26. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005 Jul 15;106(2):566–71.
27. Kasamatsu J, Azuma M, Oshiumi H, Morioka Y, Okabe M, Ebihara T, Matsumoto M, Seya T. INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinicpolycytidylic acid-stimulated accessory cells. J Immunol. 2014 Oct 15;193(10):5199–207.
28. Chaix J, Tessmer MS, Hoebe K, Fuséri N, Ryffel B, Dalod M, Alexopoulou L, Beutler B, Brossay L, Vivier E, Walzer T. Cutting edge: priming of NK cells by IL-J Immunol. 2008 Aug 1;181(3):1627–31.
29. Wei J, Xia S, Sun H, Zhang S, Wang J, Zhao H, Wu X, Chen X, Hao J, Zhou X, Zhu Z, Gao X, Gao J, Wang P, Wu Z, Zhao L, Yin Z. Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells. J Immunol. 2013 Jul 1;191(1):500–8.
30. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol. 1998 Nov;10(11):1593–8.
31. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kaliński P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000 May 1;164(9):4507–12.
32. Murugaiyan G, Saha B. IL-27 in tumor immunity and immunotherapy. Trends Mol Med. 2013 Feb;19(2):108–16.
33. Liu L, Wang S, Shan B, Shao L, Sato A, Kawamura K, Li Q, Ma G, Tagawa M. IL-27- mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J Immunol. 2008 Jul;68(1):22–9.
34. Matsui M, Kishida T, Nakano H, Yoshimoto K, Shin-Ya M, Shimada T, Nakai S, Imanishi J, Yoshimoto T, Hisa Y, Mazda O. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 2009 Mar 15;69(6):2523–30.
35. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchieri G. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 2005 Jan 15;174(2):727–34.
36. Swann JB, Hayakawa Y, Zerafa N, Sheehan KCF, Scott B, Schreiber RD, Hertzog P, Smyth MJ. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007 Jun 15;178(12):7540–9.
37. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, Moretta A, Thiel A. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol. 2005 Aug;35(8):2452–8.
38. Shimizu K, Asakura M, Fujii S. Prolonged antitumor NK cell reactivity elicited by CXCL10- expressing dendritic cells licensed by CD40L+ CD4+ memory T cells. J Immunol. 2011 May 15;186(10):5927–37.
39. Gustafsson K, Ingelsten M, Bergqvist L, Nyström J, Andersson B, Karlsson-Parra A. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res. 2008 Jul 15;68(14):5965–71.
40. Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 2013 Aug 1;73(15):4653–62.
41. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998 Mar 5;392(6671):86–9.
42. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. 2002 May 20;195(10):1289–302.
43. Morandi B, Mortara L, Chiossone L, Accolla RS, Mingari MC, Moretta L, Moretta A, Ferlazzo G. Dendritic cell editing by activated natural killer cells results in a more protective cancerspecific immune response. PLoS One. 2012 Jan;7(6):e39170.
44. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002 Feb 4;195(3):343–51.
45. Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol. 2003 Jun;33(6): 1657–66.
46. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002 Feb 4;195(3):335–41.
47. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, Lazzeri E, Lasagni L, Martini S, Rivera P, Capobianco A, Moretta L, Moretta A, Bottino C. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood. 2006 Mar 1;107(5):2030–6.
48. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003 Jan;21:685–711.
49. Van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol. 2003 Dec 1;171(11):5842–52.
50. Prins RM, Vo DD, Khan-Farooqi H, Yang M-Y, Soto H, Economou JS, Liau LM, Ribas A. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006 Dec 15;177(12):8448–55.
51. Shimizu K, Fujii S. DC therapy induces longterm NK reactivity to tumors via host DC. Eur J Immunol. 2009 Feb;39(2):457–68.
52. Hömberg N, Adam C, Riedel T, Brenner C, Flatley A, Röcken M, Mocikat R. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma. Int J Cancer. 2014 Dec 15;135(12):2825–33.
53. Van Elssen CHMJ, Oth T, Germeraad WT V, Bos GMJ, Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res. 2014 Mar 1;20(5):1095–103.
54. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006 Oct;55(9):1122–31.
55. Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanomaspecific cytotoxic T cells. J Immunother. 2011 Apr;34(3):270–8.
56. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007 Jan;25:297–336.
57. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med. 2002 Mar 4;195(5):637–41.
58. Molling JW, Langius JAE, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJJ, von Blomberg BME, Scheper RJ, van den Eertwegh AJM. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007 Mar 1;25(7):862–8.
59. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013 Feb;13(2):101–17.
60. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012 Apr;12(4):239–52.
61. Carreño LJ, Kharkwal SS, Porcelli SA. Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy. 2014 Mar;6(3):309–20.
62. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997 Nov 28;278(5343):1626–9.
63. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999 Apr 5;189(7):1121–8.
64. Faveeuw C, Trottein F. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines. Cancer Res. 2014 Mar 15;74(6):1632–8.
65. Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KCF, Capron M, Ryffel B, Faveeuw C, Leite de Moraes M, Platt F, Trottein F. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity. 2007 Oct;27(4):597–609.
66. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol. 2003 Dec;4(12):1230–7.
67. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003 Jun;17(6):1068–77.
68. Kuylenstierna C, Björkström NK, Andersson SK, Sahlström P, Bosnjak L, Paquin-Proulx D, Malmberg K-J, Ljunggren H-G, Moll M, Sandberg JK. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol. 2011 Jul;41(7):1913–23.
69. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T. Human invariant valpha24+ natural killer T cells activated by alphagalactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology. 2000 Feb;99(2):229–34.
70. Song L, Asgharzadeh S, Salo J, Engell K, Wu H, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009 Jun;119(6):1524–36.
71. Biswas SK, Allavena P, Mantovani A. Tumorassociated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013 Sep;35(5):585–600.
72. Ko H-J, Lee J-M, Kim Y-J, Kim Y-S, Lee K-A, Kang C-Y. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol. 2009 Feb 15;182(4):1818–28.
73. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol. 2010 Nov;11(11):1039–46.
74. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med. 2005 Jun 20;201(12):1973–85.
75. Schneiders FL, de Bruin RCG, Santegoets SJAM, Bonneville M, Scotet E, Scheper RJ, Verheul HMW, de Gruijl TD, van der Vliet HJ. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α. Clin Immunol. 2012 Feb;142(2):194–200.
76. Pilones KA, Aryankalayil J, Babb JS, Demaria S. Invariant natural killer T cells regulate antitumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes. J Immunother cancer. 2014 Jan;2(1):37.
77. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004 Jan;92:13–27.
78. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med. 1997 Jul 7;186(1):109–20.
79. Van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SMM. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med. 2011 Feb;17(2):65–77.
80. Fujii S-I, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004 Jun 21;199(12):1607–18.
81. Hermans IF, Silk JD, Gileadi U, Masri SH, Shepherd D, Farrand KJ, Salio M, Cerundolo V. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol. 2007 Mar 1;178(5):2721–9.
82. Montoya CJ, Jie H-B, Al-Harthi L, Mulder C, Patiño PJ, Rugeles MT, Krieg AM, Landay AL, Wilson SB. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol. 2006 Jul 15;177(2):1028–39.
83. Marschner A, Rothenfusser S, Hornung V, Prell D, Krug A, Kerkmann M, Wellisch D, Poeck H, Greinacher A, Giese T, Endres S, Hartmann G. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol. 2005 Aug;35(8):2347–57.
84. Shimizu K, Asakura M, Shinga J, Sato Y, Kitahara S, Hoshino K, Kaisho T, Schoenberger SP, Ezaki T, Fujii S. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol. 2013 Jun 1;190(11):5609–19.
85. Liu K, Idoyaga J, Charalambous A, Fujii S-I, Bonito A, Mordoh J, Wainstok R, Bai X-F, Liu Y, Steinman RM. Innate NKT lymphocytes confer superior adaptive immunity via tumorcapturing dendritic cells. J Exp Med. 2005 Dec 5;202(11):1507–16.
86. Pietra G, Romagnani C, Mazzarino P, Millo E, Moretta L, Mingari MC. Comparative analysis of NK- or NK-CTL-mediated lysis of immature or mature autologous dendritic cells. Eur J Immunol. 2003 Dec;33(12):3427–32.
87. Brigl M, Tatituri RV V, Watts GFM, Bhowruth V, Leadbetter EA, Barton N, Cohen NR, Hsu F-F, Besra GS, Brenner MB. Innate and cytokinedriven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med. 2011 Jun 6;208(6):1163–77.
88. Tyznik AJ, Tupin E, Nagarajan NA, Her MJ, Benedict CA, Kronenberg M. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol. 2008 Oct 1;181(7):4452–6.
89. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, Imamura M. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005 Oct 15;11(20):7322–7.
90. Crul M, Mathôt RA, Giaccone G, Punt CA, Rosing H, Hillebrand MX, Ando Y, Nishi N, Tanaka H, Schellens JM, Beijnen JH. Population pharmacokinetics of the novel anticancer agent KRN70Cancer Chemother Pharmacol. 2002 Apr;49(4):287–93.
91. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BME, Scheper RJ, van der Vliet HJJ, van den Eertwegh AJM, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002 Dec;8(12):3702–9.
92. Uldrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, Lew AM, Bouillet P, Strasser A, Smyth MJ, Godfrey DI. NKT cell stimulation with glycolipid antigen in vivo: costimulationdependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol. 2005 Sep 1;175(5):3092–101.
93. Parekh V V, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang C-R, Joyce S, Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest. 2005 Sep;115(9):2572–83.
94. Burdin N, Brossay L, Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1- reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol. 1999 Jun;29(6):2014–25.
95. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol. 1999 Sep 1;163(5):2387–91.
96. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002 Sep;3(9):867–74.
97. Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf IGH. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol. 2006 Aug;18(8):1279–83.
98. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol. 2014 Jul 15;193(2):961–9.
99. Van der Vliet HJJ, Molling JW, Nishi N, Masterson AJ, Kölgen W, Porcelli SA, van den Eertwegh AJM, von Blomberg BME, Pinedo HM, Giaccone G, Scheper RJ. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 2003 Jul 15;63(14):4101–6.
100. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004 Jan 15;103(2): 383–9.
101. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T. A phase I-II study of alpha-galactosylceramide- pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009 Feb 15;182(4):2492–501.
102. Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fujii S-I, Taniguchi M, Yoshino I, Nakayama T. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells. J Clin Immunol. 2012 Oct;32(5):1071–81.
103. Nicol AJ, Tazbirkova A, Nieda M. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells. Clin Cancer Res. 2011 Aug 1;17(15):5140–51.
104. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar M V. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005 May 2;201(9):1503–17.
105. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y. Phase I study of alpha-galactosylceramide- pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother. 2008 Mar;57(3):337–45.
106. Okai M, Nieda M, Tazbirkova A, Horley D, Kikuchi A, Durrant S, Takahashi T, Boyd A, Abraham R, Yagita H, Juji T, Nicol A. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alphagalactosylceramide- pulsed dendritic cells. Vox Sang. 2002 Oct;83(3):250–3.
107. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005 Mar 1;11(5):1910–7.
108. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079–86.
109. Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H. Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol. 2012 Jun;95(6):624–31.
110. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and alphagalactosylceramide- pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009 Jun;100(6):1092–8.
111. Ferreira LMR. Gammadelta T cells: innately adaptive immune cells? Int Rev Immunol. 2013 Jun;32(3):223–48.
112. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol. 2013 Feb;13(2):88–100.
113. Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom BR, Golan DE, Brenner MB. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity. 1995 Oct;3(4):495–507.
114. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev. 2007 Feb;215:59–76.
115. Braza MS, Klein B. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Br J Haematol. 2013 Jan;160(2):123–32.
116. Holoshitz J, Romzek NC, Jia Y, Wagner L, Vila LM, Chen SJ, Wilson JM, Karp DR. MHCindependent presentation of mycobacteria to human gamma delta T cells. Int Immunol. 1993 Nov;5(11):1437–43.
117. Gober H-J, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003 Jan 20;197(2):163–8.
118. Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, Guiraud M, Monsarrat B, Saulquin X, Maillet S, Estève J-P, Lopez F, Perret B, Collet X, Bonneville M, Champagne E. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005 Jan;22(1):71–80.
119. Kaur I, Voss SD, Gupta RS, Schell K, Fisch P, Sondel PM. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt’s lymphoma cells. J Immunol. 1993 Mar 1;150(5):2046–55.
120. Zhang H, Hu H, Jiang X, He H, Cui L, He W. Membrane HSP70: the molecule triggering gammadelta T cells in the early stage of tumorigenesis. Immunol Invest. 2005 Jan;34(4):453–68.
121. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879–84.
122. Lança T, Correia D V, Moita CF, Raquel H, Neves-Costa A, Ferreira C, Ramalho JS, Barata JT, Moita LF, Gomes AQ, Silva-Santos B. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood. 2010 Mar 25;115(12):2407–11.
123. Todaro M, D’Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol. 2009 Jun 1;182(11):7287–96.
124. Li Z, Xu Q, Peng H, Cheng R, Sun Z, Ye Z. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/ Fas ligand pathway. Int Immunopharmacol. 2011 Apr;11(4):496–503.
125. Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012 May;30(5):824–30.
126. Devilder M-C, Allain S, Dousset C, Bonneville M, Scotet E. Early triggering of exclusive IFNgamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J Immunol. 2009 Sep 15;183(6):3625–33.
127. Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol. 2005 Jan 1;174(1):252–60.
128. Khan MWA, Eberl M, Moser B. Potential use of γδ T cell-based vaccines in cancer immunotherapy. Front Immunol. 2014 Jan;5:512.
129. Ramstead AG, Jutila MA. Complex role of γδ T-cell-derived cytokines and growth factors in cancer. J Interferon Cytokine Res. 2012 Dec;32(12):563–9.
130. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang R-F. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007 Aug;27(2):334–48.
131. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, Hoft DF, Peng G. Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol. 2013 Mar 1;190(5):2403–14.
132. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, Schwartz T, Hunborg P, Varvares MA, Hoft DF, Hsueh EC, Peng G. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol. 2012 Nov 15;189(10):5029–36.
133. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, Shi L, Wu D, Dong C, Liu H. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 2014 Apr 1;74(7):1969–82.
134. Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, Kitamura H, Nishimura T. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol. 2010 Jul;40(7):1927–37.
135. Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R, Eto M, Nakatani T, Naito S, Yoshikai Y. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol. 2011 Jan;41(1):246–51.
136. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011 Mar 14;208(3):491–503.
137. Kabelitz D, Kalyan S, Oberg H-H, Wesch D. Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity. Oncoimmunology. 2013 Mar 1;2(3):e23304.
138. Kunzmann V, Kretzschmar E, Herrmann T, Wilhelm M. Polyinosinic-polycytidylic acidmediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons. Immunology. 2004 Jul;112(3):369–77.
139. Fowler DW, Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD. Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother. 2012 Apr;61(4):535–47.
140. Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, Nakamura H, Yamanishi H, Terada N, Okamura H. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother. 2010 Apr;33(3):287–96.
141. Cui Y, Kang L, Cui L, He W. Human gammadelta T cell recognition of lipid A is predominately presented by CD1b or CD1c on dendritic cells. Biol Direct. 2009 Jan;4:47.
142. Von Lilienfeld-Toal M, Sievers E, Bodemüller V, Mihailescu C, Märten A, Gorschlüter M, Schmidt-Wolf IGH. Coculture with dendritic cells promotes proliferation but not cytotoxic activity of gamma/delta T cells. Immunol Lett. 2005 Jun 15;99(1):103–8.
143. Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M. Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. J Clin Exp Hematop. 2007 Nov;47(2):61–72.
144. Ismaili J, Olislagers V, Poupot R, Fournié J-J, Goldman M. Human gamma delta T cells induce dendritic cell maturation. Clin Immunol. 2002 Jun;103(3 Pt 1):296–302.
145. Martino A, Casetti R, D’Alessandri A, Sacchi A, Poccia F. Complementary function of gamma delta T-lymphocytes and dendritic cells in the response to isopentenyl-pyrophosphate and lipopolysaccharide antigens. J Clin Immunol. 2005 May;25(3):230–7.
146. Leslie DS, Vincent MS, Spada FM, Das H, Sugita M, Morita CT, Brenner MB. CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med. 2002 Dec 16;196(12):1575–84.
147. Collins C, Wolfe J, Roessner K, Shi C, Sigal LH, Budd RC. Lyme arthritis synovial gam-madelta T cells instruct dendritic cells via fas ligand. J Immunol. 2005 Nov 1;175(9):5656–65.
148. Inoue S-I, Niikura M, Takeo S, Mineo S, Kawakami Y, Uchida A, Kamiya S, Kobayashi F. Enhancement of dendritic cell activation via CD40 ligand-expressing γδ T cells is responsible for protective immunity to Plasmodium parasites. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12129–34.
149. Shrestha N, Ida JA, Lubinski AS, Pallin M, Kaplan G, Haslett PAJ. Regulation of acquired immunity by gamma delta T-cell/dendritic-cell interactions. Ann N Y Acad Sci. 2005 Dec;1062:79–94.
150. Bradley LM, Dalton DK, Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol. 1996 Aug 15;157(4):1350–8.
151. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010 Sep 9;116(10):1726–33.
152. Cairo C, Surendran N, Harris KM, Mazan- Mamczarz K, Sakoda Y, Diaz-Mendez F, Tamada K, Gartenhaus RB, Mann DL, Pauza CD. Vγ2Vδ2 T cell costimulation increases NK cell killing of monocyte-derived dendritic cells. Immunology. 2014 Sep 16; doi: 10.1111/imm.12386.
153. Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδ T cells for cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology. 2014 Jan 1;3(1):e27572.
154. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. Pilot trial of interleukin- 2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother. 2011 Oct;60(10):1447–60.
155. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007 Aug 1;110(3):921–7.
156. Takahara M, Miyai M, Tomiyama M, Mutou M, Nicol AJ, Nieda M. Copulsing tumor antigenpulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. J Leukoc Biol. 2008 Mar;83(3):742–54.
157. Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother. 2010 Nov;59(11):1611–9.
158. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Kondo T, Maekawa R, Takahara M, Nieda M, Kuzushima K, Ishikawa T, Uchiyama T. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br J Haematol. 2011 Jun;153(6):796–9.